3 Stocks Improving Performance Of The Drugs Industry

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 115 points (0.7%) at 16,388 as of Friday, Feb. 28, 2014, 11:55 AM ET. The NYSE advances/declines ratio sits at 1,987 issues advancing vs. 938 declining with 158 unchanged.

The Drugs industry currently sits down 0.5% versus the S&P 500, which is up 0.6%. Top gainers within the industry include Grifols ( GRFS), up 2.8%, Amgen ( AMGN), up 2.4%, Teva Pharmaceutical Industries ( TEVA), up 1.9%, Sanofi ( SNY), up 0.9% and Novo Nordisk A/S ( NVO), up 0.9%. On the negative front, top decliners within the industry include Questcor Pharmaceuticals ( QCOR), down 7.8%, Isis Pharmaceuticals ( ISIS), down 5.0%, Intercept Pharmaceuticals ( ICPT), down 3.5%, Shire ( SHPG), down 2.5% and Illumina ( ILMN), down 1.6%.

TheStreet would like to highlight 3 stocks pushing the industry higher today:

3. Celgene Corporation ( CELG) is one of the companies pushing the Drugs industry higher today. As of noon trading, Celgene Corporation is up $2.51 (1.6%) to $164.18 on light volume. Thus far, 1.0 million shares of Celgene Corporation exchanged hands as compared to its average daily volume of 3.0 million shares. The stock has ranged in price between $161.81-$164.20 after having opened the day at $162.55 as compared to the previous trading day's close of $161.67.

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies to treat cancer and immune-inflammatory related diseases in the United States and internationally. Celgene Corporation has a market cap of $65.0 billion and is part of the health care sector. Shares are down 4.3% year-to-date as of the close of trading on Thursday. Currently there are 24 analysts who rate Celgene Corporation a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates Celgene Corporation as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, notable return on equity, reasonable valuation levels, expanding profit margins and good cash flow from operations. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Celgene Corporation Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, Merck ( MRK) is up $0.59 (1.0%) to $57.25 on light volume. Thus far, 3.6 million shares of Merck exchanged hands as compared to its average daily volume of 12.6 million shares. The stock has ranged in price between $56.67-$57.37 after having opened the day at $56.73 as compared to the previous trading day's close of $56.66.

Merck & Co., Inc. provides various health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products worldwide. Merck has a market cap of $164.4 billion and is part of the health care sector. Shares are up 13.2% year-to-date as of the close of trading on Thursday. Currently there are 7 analysts who rate Merck a buy, no analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates Merck as a buy. Among the primary strengths of the company is its solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Merck Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, Johnson & Johnson ( JNJ) is up $1.02 (1.1%) to $92.38 on light volume. Thus far, 2.5 million shares of Johnson & Johnson exchanged hands as compared to its average daily volume of 8.3 million shares. The stock has ranged in price between $91.06-$92.51 after having opened the day at $91.42 as compared to the previous trading day's close of $91.36.

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the health care field worldwide. The company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. Johnson & Johnson has a market cap of $257.7 billion and is part of the health care sector. Shares are down 0.2% year-to-date as of the close of trading on Thursday. Currently there are 9 analysts who rate Johnson & Johnson a buy, no analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates Johnson & Johnson as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, increase in stock price during the past year, impressive record of earnings per share growth, compelling growth in net income and expanding profit margins. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Johnson & Johnson Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

null

More from Markets

Trump Takes Aim at Auto Imports; Markets End Mixed -- ICYMI

Trump Takes Aim at Auto Imports; Markets End Mixed -- ICYMI

Video: What Oprah's Content Partnership With Apple Means for the Rest of Tech

Video: What Oprah's Content Partnership With Apple Means for the Rest of Tech

REPLAY: Jim Cramer on the Markets, Oil, Starbucks, Tesla, Okta and Red Hat

REPLAY: Jim Cramer on the Markets, Oil, Starbucks, Tesla, Okta and Red Hat

Flashback Friday: The Market Movers

Flashback Friday: The Market Movers

OPEC Deal Doesn't Boost Production Enough to Drive Down Crude, Gasoline Prices

OPEC Deal Doesn't Boost Production Enough to Drive Down Crude, Gasoline Prices